MDT

82.5

-0.08%↓

VEEV

215.64

-2.19%↓

A

102.36

-0.28%↓

WBA

10.88

+0.65%↑

CHE

579.57

-0.25%↓

MDT

82.5

-0.08%↓

VEEV

215.64

-2.19%↓

A

102.36

-0.28%↓

WBA

10.88

+0.65%↑

CHE

579.57

-0.25%↓

MDT

82.5

-0.08%↓

VEEV

215.64

-2.19%↓

A

102.36

-0.28%↓

WBA

10.88

+0.65%↑

CHE

579.57

-0.25%↓

MDT

82.5

-0.08%↓

VEEV

215.64

-2.19%↓

A

102.36

-0.28%↓

WBA

10.88

+0.65%↑

CHE

579.57

-0.25%↓

MDT

82.5

-0.08%↓

VEEV

215.64

-2.19%↓

A

102.36

-0.28%↓

WBA

10.88

+0.65%↑

CHE

579.57

-0.25%↓

Search

Amicus Therapeutics Inc

Chiusa

SettoreSettore sanitario

6.82 2.1

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

6.78

Massimo

6.87

Metriche Chiave

By Trading Economics

Entrata

21M

15M

Vendite

8.2M

150M

EPS

0.09

Margine di Profitto

9.845

Dipendenti

499

EBITDA

286K

22M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+136.72% upside

Dividendi

By Dow Jones

Utili prossimi

8 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-792M

2.1B

Apertura precedente

4.72

Chiusura precedente

6.82

Notizie sul Sentiment di mercato

By Acuity

50%

50%

134 / 385 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Amicus Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 apr 2025, 15:57 UTC

I principali Market Mover

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

18 apr 2025, 20:42 UTC

Acquisizioni, Fusioni, Takeovers

What Bill Ackman Sees in Hertz and Why He's Betting Big on the Rental-Car Company -- Barrons.com

18 apr 2025, 20:32 UTC

Notizie principali

Trump to Replace Acting IRS Commissioner -- 2nd Update

18 apr 2025, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

18 apr 2025, 19:52 UTC

Discorsi di Mercato

Correction to Aluminum Fee Rising Slower Than Forecast Article

18 apr 2025, 19:40 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

18 apr 2025, 19:40 UTC

Discorsi di Mercato

Aluminum Fee Rising Slower Than Forecast From Tariff -- Market Talk

18 apr 2025, 18:51 UTC

Utili

Netflix Has Made Several Risky Bets. Earnings Show They've Paid Off. -- Barrons.com

18 apr 2025, 18:40 UTC

Acquisizioni, Fusioni, Takeovers

What Bill Ackman Sees in Hertz and Why He's Betting Big on the Rental-Car Company -- Barrons.com

18 apr 2025, 18:29 UTC

Discorsi di Mercato

Shorter Duration Seen as Way to Shield Portfolio From Political Turbulence -- Market Talk

18 apr 2025, 18:21 UTC

Notizie principali

Ford Halts Shipments of F-150s and Other Models to China -- WSJ

18 apr 2025, 17:31 UTC

Notizie principali

Trump to Replace Acting IRS Commissioner -- WSJ

18 apr 2025, 17:24 UTC

Acquisizioni, Fusioni, Takeovers

Capital One's Discover Takeover Gets the Green Light. The Two Will Create the 6th-Largest U.S. Bank. -- Barrons.com

18 apr 2025, 17:22 UTC

Acquisizioni, Fusioni, Takeovers

Capital One's $35 Billion Discover Takeover Clears Final Approvals -- Barrons.com

18 apr 2025, 16:00 UTC

Notizie principali

Trump's Trade War Threatens One of America's Top Energy Exports -- WSJ

18 apr 2025, 15:53 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

Bill Ackman Teases Prospect of Uber, Hertz Partnership -- Update

18 apr 2025, 15:46 UTC

Utili

Tech's Problems in China Are Getting Worse. These Companies Are Most at Risk. -- Barrons.com

18 apr 2025, 15:10 UTC

Discorsi di Mercato
Utili

Netflix Momentum Likely To Continue Thanks To Growing Subscriber Base -- Market Talk

18 apr 2025, 14:46 UTC

Utili

Tech Earnings Have Good News for Chip Stocks, So Far. And 1 Warning. -- Barrons.com

18 apr 2025, 14:24 UTC

Discorsi di Mercato
Utili

Netflix Still Has Room to Add Subscribers -- Market Talk

18 apr 2025, 14:17 UTC

Utili

Apple Is an Efficiency Champion. This Company Is Closing in on Its Crown. -- Barrons.com

18 apr 2025, 13:55 UTC

Notizie principali

EU Delayed Punishing Apple, Meta Just Before Trade Talks Started -- WSJ

18 apr 2025, 11:21 UTC

Utili

Netflix Stock Jumps on Earnings Beat. Why Tariffs Won't Hurt the Streamer. -- Barrons.com

18 apr 2025, 11:00 UTC

Notizie principali

Amazon's Vast Empire Gives It a Leg Up in the Trade War -- Heard on the Street -- WSJ

18 apr 2025, 11:00 UTC

Notizie principali

Johnson & Johnson Pivots Its AI Strategy -- WSJ

18 apr 2025, 10:36 UTC

Notizie principali

Trump Signals China's Xi Has Reached Out About a Trade Deal. Here's the Latest on Tariffs. -- Barrons.com

18 apr 2025, 10:26 UTC

Notizie principali

Why World Leaders Are Pulling Their Punches in the Trade War -- Update

18 apr 2025, 09:30 UTC

Notizie principali

Now Streaming on Netflix: A Show Where Profits Trump the Trade War -- Heard on the Street -- Update

18 apr 2025, 08:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

18 apr 2025, 06:52 UTC

Discorsi di Mercato

Nikkei Rises 1.0%, Led by Pharma, Shipping Stocks -- Market Talk

Confronto tra pari

Modifica del prezzo

Amicus Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

136.72% in crescita

Previsioni per 12 mesi

Media 15.86 USD  136.72%

Alto 20 USD

Basso 12 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Amicus Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

6

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

6.7 / 6.89Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

134 / 385 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.